metaPreg - Natalizumab during pregnancy

Natalizumab

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	5.51 [1.10, 27.66]	-	1 study	9	54	not evaluable	ROB	10.50 [1.43; .]
2 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	0.84 [0.46, 1.52]	31%	2 studies	235	111	not evaluable	ROB	-
Low birth weight (< 2500g)	-	-	0 study					-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	-	-	0 study					-
Maternal consequences (as a whole)	3.50 [1.02, 12.05]	-	1 study	13	54	not evaluable	ROB	6.46 [1.15; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Elective/induced termination of pregnancy	2.26 [0.33, 15.52]	82%	2 studies	48	147	not evaluable	ROB	-
4 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study